The long-term goal of this research is to elucidate the mechanism of action of cis-diammineddichloroplatinum (II), cis-DDP or cisplatin, a leading anti-cancer drug used to treat testicular tumors and a paradigm for successful chemotherapy. The major underlying hypothesis is that the biological activity derives from the formation and persistence of cisplatin- DNA adducts, mainly 1,2-intrastrand d(GpG) and d(ApG) cross-links. Geometric information about these adducts in several of 16 possible N1GGN2 and N11AGN2 sequence contexts and their binding to cellular proteins will be provided. Novel synthetic routes to site-specifically platinated duplex DNAs are presented as well as thermodynamic, kinetic, and NMR and X-ray structural methods for characterizing their complexes with proteins. Among proteins that bind specifically major cisplatin-DNA adducts and affect cellular processing are those containing high-mobility group (HMG) domains. HMG domain proteins shield platinum adducts from nucleotide excision repair (NER) and help elongate transcripts from chromatin. The ability of cisplatin-DNA intrastrand cross-links to be excised by NER and to block transcription will be investigated with reconstituted in vitro assays. Probes containing specific adducts and strategically placed photocross-linking agents will be introduced to identify factors contacting platinated DNA. Extracts from tumor and normal testis tissue from a new breed of mice that develops testicular cancer will be prepared for NER studies to test the hypothesis that poor repair of cisplatin adducts underlies its selective toxicity. Parallel work will be performed with cultured human testis cell. The (TTAGGG)n repeating sequence in human telomeres is a likely target for cisplatin. We shall investigate telomere length maintenance as a contributing factor to the cisplatin molecular mechanism by studying the platination of this sequence in duplex DNAs. The effect of cisplatin on telomere binding proteins (TBPs) such as TRF1 and TRF2 will be studied in cells or in situ immunofluorescence techniques. In vitro binding of TBPs to probes with embedded site-specifically platinated telomere sequences will also be examined. An additional aim, to improve the selective binding of HMG-domain proteins to cisplatin 1,2-cross-links, will be met by site-directed mutagenesis based on a recent structure of a complex between HMG1 domain A and a platinated 16-mer duplex. Phage display will provide additional peptides selected for their strong binding to cis0platin-cross-links. These protein constructs will be over- expressed in mammalian cells to evaluate whether they affect cisplatin sensitivity, ultimately for combined chemotherapy/gene therapy applications in human cancer. With a newly devised transcription inhibition assay have a fast fluorescent readout, combinatorial libraries of platinum compounds will be screened for anti-cancer drug candidates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA034992-19
Application #
6341863
Study Section
Metallobiochemistry Study Section (BMT)
Program Officer
Lees, Robert G
Project Start
1983-01-01
Project End
2004-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
19
Fiscal Year
2001
Total Cost
$620,202
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Ling, Xiang; Chen, Xing; Riddell, Imogen A et al. (2018) Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. Nano Lett 18:4618-4625
Zhou, Wen; Almeqdadi, Mohammad; Xifaras, Michael E et al. (2018) The effect of geometric isomerism on the anticancer activity of the monofunctional platinum complex trans-[Pt(NH3)2(phenanthridine)Cl]NO3. Chem Commun (Camb) 54:2788-2791
Hucke, Anna; Park, Ga Young; Bauer, Oliver B et al. (2018) Interaction of the New Monofunctional Anticancer Agent Phenanthriplatin With Transporters for Organic Cations. Front Chem 6:180
Awuah, Samuel G; Riddell, Imogen A; Lippard, Stephen J (2017) Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity. Proc Natl Acad Sci U S A 114:950-955
Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471
Patra, Malay; Awuah, Samuel G; Lippard, Stephen J (2016) Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo. J Am Chem Soc 138:12541-51
Riddell, Imogen A; Johnstone, Timothy C; Park, Ga Young et al. (2016) Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin. Chemistry 22:7574-81
Johnstone, Timothy C; Suntharalingam, Kogularamanan; Lippard, Stephen J (2016) The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 116:3436-86
Patra, Malay; Johnstone, Timothy C; Suntharalingam, Kogularamanan et al. (2016) A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. Angew Chem Int Ed Engl 55:2550-4
Riddell, Imogen A; Agama, Keli; Park, Ga Young et al. (2016) Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. ACS Chem Biol 11:2996-3001

Showing the most recent 10 out of 141 publications